Clinical outcomes and patient satisfaction after hybrid micro-monovision using extended-range-of-vision IOL in one eye and monofocal IOL in contralateral eye

Session Details

Session Title: Presented Poster Session: EDOF IOLs

Venue: Poster Village: Pod 1

First Author: : R.Arra INDIA

Co Author(s): :    S. Ganesh   S. Brar                    

Abstract Details

Purpose:

To study the clinical outcomes and patient satisfaction in hybrid micro-monovision with Extended Range of Vision (ERV) IOL in one eye and a monofocal IOL in the contralateral eye

Setting:

Nethradhama Superspeciality Eye Hospital, Bengaluru

Methods:

It was a prospective interventional study in which 15 patients (mean age:62.5 years)were implanted with an Extended Range of Vision (ERV) IOL in the non-dominant eye & a monofocal aspheric IOL in the dominant eye following phacoemulsification. Micro-monovision was planned with a target post-op refraction in the non- dominant eye as -0.75D. Patients were tested for corrected/ uncorrected distant, intermediate & near visual acuity, reading performance(using Salzburg Reading Desk), defocus curve & contrast sensitivity tested at 1 week, 1 month & 3 month post-operatively

Results:

At 3 month post-op, the binocular mean uncorrected distant, near & intermediate(60cm) visual acuity were -0.03 ± 0.09, 0.15 ± 0.11 & 0.04± 0.09 logMAR respectively. Visual acuity remained 0.2 logMAR or better throughout defocus range of -3D to +3D. Contrast sensitivity and mean reading speeds improved over time. Minimal dysphotopsia was noted initially in some patients which resolved over time. No patient was prescribed glasses or contact lenses for fine tuning of distance or near vision. No eye underwent YAG capsulotomy for PCO uptil the end of 3 months.

Conclusions:

At 3 months, patients had excellent unaided vision at all distances with good contrast sensitivity and minimal dysphotopsia suggesting that this combination of one eye ERV IOL and contralateral eye monofocal IOL, may provide satisfactory outcomes with good tolerance to micro-monovision.

Financial Disclosure:

None